Columvi (glofitamab-gxbm)▼
Columvi is a CD20xCD3 T-cell engaging bispecific antibody. Columvi was the first fixed-duration bispecific antibody to receive accelerated approval by the FDA and conditional marketing authorisation in Europe to treat people with R/R DLBCL after two or more lines of systemic therapy. Columvi is approved in more than 50 countries for 3L+ DLBCL.
Solutions
Pharma Products
:quality(90)/)
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.